Costs Evolution Of Cancer Therapies In Europe From 2004 To 2014

  • Tetafort A
  • Aubert J
  • Perrot D
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Analyze the evolution of cancer therapies costs, in Germany, France, Italy and UK. Methods: Drugs included within the analysis were selected using two criteria: their rate of use in shortlisted indications (breast, colorectal, non-small cell lung cancer, chronic myeloid and lymphocytic leukemia) and their significant turnovers in Germany, France, Italy, and UK. IMS-MIDASTM, a multicountry database, was used to extract drug manufacturer prices and sales. Sales figures were splitted by indications using IMS-Oncology Analyzer™, a retrospective, longitudinal cancer treatment database and then, average baskets of drugs per indication have been built for each country. These baskets of drugs were compared between countries to illustrate the evolution and differences of cancer costs in each indication, considering both price and prescribing behavior changes. Results: Differences in composition of baskets for a same indication highlighted heterogeneous prescribing behaviors between countries. Additionally, various prices per product from one country to another led to differences of cancer management costs. Last, a macroeconomic analysis noted pricing policies generated savings of 10% in France, 6% in Italy, and 1% in the UK over the studied period. Despite price reduction being the highest in France, this analysis also showed that application of Italian or British prices to the French average basket of drugs could have led to potential savings of 15%. Conclusions: Despite old drugs prices reductions, the cancer management costs were constantly increasing in the last decade, due to therapeutic innovations. Indeed, France was the country applying the strongest price decreases (10%) but also the one with the earliest use of therapeutic innovations, generating the growth of cancer management cost. Also, the application of Italian or British prices to the French average baskets of drugs could have led to potential savings, this being explained by high launch prices in France.

Cite

CITATION STYLE

APA

Tetafort, A., Aubert, J., Perrot, D., Brigot, G., Kolahi, C., & Ansolabehere, X. (2016). Costs Evolution Of Cancer Therapies In Europe From 2004 To 2014. Value in Health, 19(7), A723. https://doi.org/10.1016/j.jval.2016.09.2155

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free